A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title:

A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of Intravenous NBF 006 in Patients With Non-Small Cell Lung, Pancreatic, or Colorectal Cancer Followed by a Dose Expansion Study in Patients With KRAS-Mutated Non-Small Cell Lung Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03819387
• Other study ID #: NBF-006-001
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: March 18, 2019
• Est. completion date: August 2024

Study information

• Verified date: August 2023
• Source: Nitto BioPharma, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-controlled study conducted in two parts - Part A (dose escalation) followed by Part B (dose expansion).

Description:

Patients in Part A will have previously treated progressive or metastatic NSCLC, pancreatic, or colorectal cancer, with or without KRAS mutation. Five dose levels will be explored. In dose level 5, only patients with previously-treated NSCLC with KRAS mutation will be included.

Patients in Part B must have previously treated NSCLC with confirmed KRAS mutation. Two dose levels will be explored further in Part B. Twenty (20) patients will be enrolled in Part B, with 10 patients enrolled in each of the two cohorts. Once dose level 5 has been confirmed to be safe in Part A (i.e. 0-1 DLT in 6 patients), an additional 4 patients will then be enrolled for a planned total of 24 patients in Part B.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 44
• Est. completion date: August 2024
• Est. primary completion date: March 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Part A: Patients with histologically or cytologically confirmed progressive or metastatic NSCLC, pancreatic, or colorectal cancer that have failed standard treatment and for which no other effective treatment is available or appropriate for the patient up to dose level 4. In dose level 5, patients with histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment available or appropriate for the patient.

Part B: Patients with histologically or cytologically confirmed progressive or metastatic NSCLC with documented KRAS-mutant genotype, who have failed standard treatment and have no other effective treatment available or appropriate for the patient.

2. Eastern Cooperative Oncology Group performance status of 0-2.

3. Men and women = 18 years of age.

4. Patients must have recovered from all acute adverse effects (excluding alopecia) of prior therapies to baseline or = Grade 1 prior to study entry.

5. Adequate bone marrow function, defined as an absolute neutrophil count (ANC) = 1.5 x 109/L and a platelet count = 100 x 109/L.

6. Adequate renal function, defined as serum creatinine = 1.5 x upper limit of normal (ULN) for the institution or calculated creatinine clearance [Cockcroft-Gault method] must be = 60 mL/min/1.73 m². If serum creatinine is >1.5 x ULN, then creatinine clearance can be calculated from a 24-hour urine collection.

7. Adequate hepatic function, defined as total bilirubin = 1.5 mg/dL and alanine transaminase (ALT) and aspartate transaminase (AST) = 2.5 x ULN, or = 5 x ULN if known liver metastases.

8. Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.

9. Patients with reproductive potential must agree to use at least one form of highly effective contraception prior to study entry and for up to 30 days beyond the last administration of study drug.

10. Patients must be capable of providing informed consent and must be willing to provide written informed consent prior to the start of any study-specific procedures.

11. All patients must have measurable tumor per RECIST 1.1.

12. Agree to adhere to all study protocol requirements.

Exclusion Criteria:

1. Prior chemotherapy, radiation therapy, or investigational therapy within 4 weeks (exception: 6 weeks for nitrosoureas or mitomycin C); or prior non-cytotoxic therapy within 5 drug half-lives (or 4 weeks, whichever is shorter); or monoclonal antibodies within 4 weeks prior to the first dose of study treatment.

2. Concurrent use of any other investigational agent.

3. Known or clinically suspected central nervous system or leptomeningeal metastases, unless irradiated or treated a minimum of 4 weeks prior to first study treatment and stable without requirement of corticosteroids for > 1 week.

4. Pregnant or breast feeding. A negative pregnancy test must be documented at baseline for women of childbearing potential. Patients may not breast-feed infants while on this study.

5. Significant cardiovascular disease or condition, including:

1. Congestive heart failure currently requiring therapy

2. Need for antiarrhythmic medical therapy for ventricular arrhythmia

3. Severe conduction disturbance

4. Angina pectoris requiring therapy

5. QTc interval > 450 msec (males) or > 470 msec (females) Fridericia's correction.

Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g. bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.

6. History of congenital long QT syndrome or congenital short QT syndrome

7. Uncontrolled hypertension (per the Investigator's discretion)

8. Class III or IV cardiovascular disease according to the New York Heart Association's Functional Criteria

9. Myocardial infarction within 6 months prior to first study drug administration

6. Known history of human immunodeficiency virus or active infection with hepatitis B virus or hepatitis C virus.

7. Known uncontrolled intercurrent illnesses, including uncontrolled viral influenza and COVID 19, systemic bacterial infections, and fungal infections.

8. Psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.

9. Known allergic reactions to H1/H2 antagonists.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Colorectal Cancer
• Colorectal Neoplasms
• Lung Neoplasms
• Non-Small Cell Lung Cancer
• Pancreatic Cancer

Intervention

Drug:
• NBF-006
Intravenous infusion, once-weekly x 4 consecutive weeks, every 6 weeks

Locations

Country	Name	City	State
United States	NEXT Oncology - Austin	Austin	Texas
United States	Beverly Hills Cancer Center	Beverly Hills	California
United States	Mary Crowley Cancer Research Center	Dallas	Texas
United States	NEXT Oncology - Virginia	Fairfax	Virginia
United States	UC San Diego Moores Cancer Center	La Jolla	California
United States	Vanderbilt-Ingram Cancer Center	Nashville	Tennessee
United States	NEXT Oncology - San Antonio	San Antonio	Texas
United States	Moffitt Cancer Center	Tampa	Florida
United States	University of Toledo, Eleanor N. Dana Cancer Center	Toledo	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Nitto BioPharma, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	To evaluate correlation between biomarkers and clinical outcome	analysis of ADAs, immune activation biomarkers, GSTP knockdown, and other biomarker activity	Number of days from date of first dose to 30 days after last treatment
Other	To evaluate correlation between KRAS mutations and clinical outcome		Number of days from date of first dose to 30 days after last treatment
Primary	Number of patients with treatment-related adverse events as assessed by CTCAE v5.0		Change in the incidence and severity of adverse events related to study treatment from baseline to 4 weeks following last dose
Secondary	Best Overall Response per RECIST 1.1	The rate of complete remission (CR) + partial remission (PR) + stable disease (SD)	Number of days from date of first dose to 30 days after last treatment
Secondary	Pharmacokinetic parameters for siRNA	Peak Plasma Concentration (Cmax)	Up to 72 hours from start of infusion on Cycle 1, Day 1 and Day 22 and prior to infusion Cycle 1, Day 8 and Cycle 2, Day 1
Secondary	Additional pharmacokinetic parameters for siRNA	Area under the plasma concentration versus time curve (AUC)	Up to 72 hours from start of infusion on Cycle 1, Day 1 and Day 22 and prior to infusion Cycle 1, Day 8 and Cycle 2, Day 1